Answers are grounded in this paper and cite their sources.
Following venous thromboembolism (VTE), predictive biomarker testing for risk assessment is hampered by the presence of anticoagulation. This study aims to remove in vitro interference caused by direct oral anticoagulants (DOACs) with DOAC-Stop, enabling thrombin generation testing during anticoagulation. Platelet-poor plasma was collected approximately 3 months after VTE diagnosis from adults who were therapeutically anticoagulated with apixaban or rivaroxaban. Thrombin generation testing was performed using ST-Genesia ThromboScreen, following use of DOAC-Stop. A total of 251 patients were included (mean age 55.4 years, 54.2% male). Patients with thrombophilia and/or family history of VTE demonstrated hypercoagulable thrombin generation parameters. A total of 165 patients (65.7%) were classified as clinically “high risk,” defined as one or more of unprovoked pulmonary embolism (PE) and/or proximal deep vein thrombosis (DVT), family history of VTE, personal prior history of VTE, and hereditary thrombophilia, with remaining cases considered “low-risk” VTE. The “high-risk” group demonstrated increased peak height, endogenous thrombin potential, and velocity index compared with the “low-risk” cohort. About 52.2% (n = 131/251) of all patients subsequently ceased anticoagulation, with five episodes of unprovoked recurrence occurring within 1 year of cessation. These patients had higher median peak height (139.4 vs. 104.6%, p = 0.043, percentile difference − 34.8, 95% confidence interval (CI): [− 68.4, − 1.81]) and ETP (119.5 vs. 103.7%, p = 0.006, percentile difference: − 27.5, 95% CI: [− 43.5, − 11.3]) without thrombomodulin. This study provides evidence that thrombin generation testing after DOAC-Stop can identify hypercoagulable VTE patients without interrupting anticoagulation. Thrombin generation was increased in several groups with clinical risk factors associated with hypercoagulability. Key thrombin generation parameters were increased and associated with unprovoked VTE recurrence in patients who later stopped anticoagulation. Larger confirmatory studies are required.
No takes yet. Share an insight, caveat, or question.
Brook et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: